{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T02:51:40Z","timestamp":1790563900790,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jns.2026.126087","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:52:25Z","timestamp":1783439545000},"page":"126087","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Early use of low dose rituximab in anti acetylcholine receptor generalized myasthenia gravis in South Wales \u2013 A retrospective study"],"prefix":"10.1016","volume":"489","author":[{"given":"Rana Alnasser","family":"Alsukhni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aseel","family":"Al-Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marguerite","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jns.2026.126087_bb0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"1","key":"10.1016\/j.jns.2026.126087_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102712","article-title":"Update in immunosuppressive therapy of myasthenia gravis","volume":"20","author":"Lascano","year":"2021","journal-title":"Autoimmun. Rev."},{"issue":"6","key":"10.1016\/j.jns.2026.126087_bb0015","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2026.126087_bb0020","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","article-title":"A clinical therapeutic trial of cyclosporine in myasthenia gravisa","volume":"681","author":"Tindall","year":"1993","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.jns.2026.126087_bb0025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","article-title":"A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis","volume":"87","author":"Pasnoor","year":"2016","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jns.2026.126087_bb0030","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jns.2026.126087_bb0035","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","article-title":"Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis","volume":"82","author":"Yoshikawa","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.jns.2026.126087_bb0040","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","article-title":"Myasthenia gravis: Association of British Neurologists\u2019 management guidelines","volume":"15","author":"Sussman","year":"2015","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.jns.2026.126087_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1404191","article-title":"Targeting autoimmune mechanisms by precision medicine in myasthenia gravis","volume":"15","author":"Cavalcante","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2026.126087_bb0050","first-page":"14","article-title":"Rituximab treatment in myasthenia gravis","author":"Vesperinas-Castro","year":"2023","journal-title":"Front. Neurol."},{"issue":"10","key":"10.1016\/j.jns.2026.126087_bb0055","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jns.2026.126087_bb0060","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refractory myasthenia gravis to rituximab: a retrospective study","volume":"4","author":"Nowak","year":"2011","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"3","key":"10.1016\/j.jns.2026.126087_bb0065","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/mus.26156","article-title":"Rituximab in refractory myasthenia gravis: extended prospective study results","volume":"58","author":"Beecher","year":"2018","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.jns.2026.126087_bb0070","doi-asserted-by":"crossref","first-page":"E376","DOI":"10.1212\/WNL.0000000000013121","article-title":"Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis","volume":"98","author":"Nowak","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2026.126087_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.686466","article-title":"Short- and long-lived autoantibody-secreting cells in autoimmune neurological disorders","volume":"12","author":"Zografou","year":"2021","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.jns.2026.126087_bb0080","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.kint.2019.12.025","article-title":"Anti-CD20\u2013mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives","volume":"97","author":"Crickx","year":"2020","journal-title":"Kidney Int."},{"issue":"11","key":"10.1016\/j.jns.2026.126087_bb0085","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurol."},{"issue":"8","key":"10.1016\/j.jns.2026.126087_bb0090","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis","volume":"77","author":"Brauner","year":"2020","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.jns.2026.126087_bb0095","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2026.126087_bb0100","doi-asserted-by":"crossref","DOI":"10.1177\/11795735211016080","article-title":"Effective early treatment of AChR antibody-positive myasthenia gravis with rituximab; the experience from a neuroimmunology clinic in a developing country","volume":"13","author":"Mathew","year":"2021","journal-title":"J. Cent. Nerv. Syst. Dis."},{"issue":"7_supplement_1","key":"10.1016\/j.jns.2026.126087_bb0105","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000205956","article-title":"Trial design and impact on study outcome: post-hoc analysis of the BeatMG study based on RINOMAX trial criteria (P4\u201311.004)","volume":"102","author":"Roy","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2026.126087_bb0110","series-title":"Rituximab Bio-Similar for the Treatment of Myasthenia Gravis (Adults)","author":"Clinical Commissioning Policy Statement","year":"2026"},{"issue":"4","key":"10.1016\/j.jns.2026.126087_bb0115","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2026.126087_bb0120","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/pn-2025-004655","article-title":"Association of British Neurologists (ABN) autoimmune myasthenia gravis management guidelines (2025 update)","author":"Jacob","year":"2025","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.jns.2026.126087_bb0125","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231213240","article-title":"Guideline for the management of myasthenic syndromes","author":"Wiendl","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jns.2026.126087_bb0130","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s10072-019-03746-1","article-title":"Italian recommendations for the diagnosis and treatment of myasthenia gravis","author":"Evoli","year":"2019","journal-title":"Neurol. Sci."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26003692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26003692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:08:48Z","timestamp":1786219728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X26003692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":26,"alternative-id":["S0022510X26003692"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.126087","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early use of low dose rituximab in anti acetylcholine receptor generalized myasthenia gravis in South Wales \u2013 A retrospective study","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.126087","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"126087"}}